|
2025
|
Invention
|
Camptothecin conjugates.
Antibody conjugates with camptothecin compounds are described, with met... |
|
|
Invention
|
Cd25 antibodies, antibody drug conjugates, and uses thereof.
Antigen binding proteins such as an... |
|
|
Invention
|
Cd25 antibodies, antibody-drug conjugates, and uses thereof. Antigen binding proteins such as ant... |
|
|
Invention
|
Anti-avb6 antibodies and antibody-drug conjugates.
Provided are novel anti-αvβ6 antibodies and a... |
|
|
Invention
|
Methods of treating cancer using fusion proteins specific for cd137 and cd228. The disclosure pro... |
|
|
Invention
|
Methods of treating cancers using anti-cd30 antibody-drug conjugates. Provided herein are antibod... |
|
|
Invention
|
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer. Prov... |
|
|
Invention
|
Antibody-drug conjugates. Provided herein are methods for reducing the likelihood and/or severity... |
|
2024
|
Invention
|
Methods of treating egfr mutant cancers. The present disclosure provides methods of treating a ca... |
|
|
Invention
|
Multispecific egfr antibodies and use in the treatment of cancer. Provided herein are methods of ... |
|
|
Invention
|
Selective drug release from internalized conjugates of biologically active compounds.
The invent... |
|
|
Invention
|
Chemotherapeutic compounds and methods of use. The present disclosure describes novel aminonucleo... |
|
|
Invention
|
Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates. Methods for using ... |
|
|
Invention
|
Treating locally advanced or metastatic urothelial cancer with anti-191p4d12 antibody drug conjug... |
|
|
Invention
|
Targeted degrader molecules and ligand drug conjugates thereof. Targeted degrader compounds are d... |
|
|
Invention
|
Ceacam5 antibody-drug conjugates and methods of use thereof.
The present invention relates to an... |
|
|
Invention
|
Methods of treating cancer using anti-her2 antibody-drug conjugates. Provided herein are methods ... |
|
|
Invention
|
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates.
Methods for the treat... |
|
|
Invention
|
Antibodies that bind gamma-delta t cell receptors for the treatment of cancer. In some embodiment... |
|
|
Invention
|
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics.
The present inventio... |
|
|
Invention
|
Anti-cd228 antibodies and antibody-drug conjugates.
Provided are novel anti-CD228 antibodies and... |
|
|
Invention
|
Sting agonist compounds and conjugates thereof. STING agonist compounds of Formula (A) are descri... |
|
|
Invention
|
Production cell lines with targeted integration sites. The present disclosure relates to Chinese ... |
|
|
Invention
|
Methods of treating cancer with anti-tigit antibodies. Provided herein are methods of treating ca... |
|
|
Invention
|
Methods of treating cancer using anti-her2 antibody-drug conjugates and her2 kinase inhibitors. P... |
|
|
Invention
|
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates.
Compounds an... |
|
|
Invention
|
Drug conjugates with self-stabilizing linkers having improved physiochemical properties.
Compoun... |
|
2023
|
Invention
|
Anthracycline antibody conjugates.
The present disclosure provides, inter alia, antibody drug co... |
|
|
Invention
|
Targeted delivery of tertiary amine-containing drug substances.
Compounds and compositions are d... |
|
|
Invention
|
Compositions and methods for targeting cancer stem cells.
Compositions and methods for treating ... |
|
|
Invention
|
Compositions and methods for targeting cancer stem cells.
The present invention provides methods... |
|
|
Invention
|
Glycan-interacting compounds and methods of use.
The present invention provides glycan-interacti... |
|
|
Invention
|
Camptothecin peptide conjugates.
Provided herein are Camptothecin Conjugates, Camptothecin-Linke... |
|
|
Invention
|
Beta-glucuronide-linker drug conjugates.
Ligand Drug conjugate compounds comprising a β-glucuron... |
|
|
Invention
|
Humanized antibodies to liv-1 and use of same to treat cancer.
The invention provides humanized ... |
|
|
Invention
|
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy.
The present discl... |
|
|
Invention
|
Immunostimulatory compounds and conjugates.
The present disclosure provides, inter alia, antibod... |
|
|
P/S
|
Pharmaceutical preparations for use in humans for the treatment of cancer and immunological disea... |
|
|
P/S
|
Pharmaceutical preparations for the treatment and diagnosis of cancer and immunological diseases. |
|
|
P/S
|
Pharmaceutical research and development services; biotechnology research, namely, pharmaceutical ... |
|
|
P/S
|
Pharmaceutical research and development services;
biotechnology research, namely, pharmaceutical... |
|
|
P/S
|
Pharmaceutical preparations for the treatment and diagnosis
of cancer and immunological diseases. |
|
|
Invention
|
Immunomodulatory antibody-drug conjugates.
The present disclosure provides, inter alia, antibody... |
|
|
P/S
|
Pharmaceutical preparations for the treatment and diagnosis of cancer and immunological diseases |
|
|
Invention
|
Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with ant... |
|
2022
|
Invention
|
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody ... |
|
|
Invention
|
Improved antibody masking domains.
Improved masking domains and masked antibodies comprising imp... |
|
|
Invention
|
Methods of treating multiple myeloma.
Provided herein are methods of treating multiple myeloma (... |
|
|
Invention
|
Treatment for cancer.
This disclosure relates to methods of treating cancer using a combination ... |
|
|
Invention
|
Antibody masking domains.
Masking domains and masked antibodies comprising masking domains are p... |
|
|
P/S
|
Providing medical information; providing medical information on pharmaceuticals |
|
|
P/S
|
Providing healthcare information |
|
|
Invention
|
Anti-alpp/alppl2 antibodies and antibody-drug conjugates.
Antigen binding proteins such as antib... |
|
|
P/S
|
Providing a website featuring information in the field of cancer and cancer treatment; providing ... |
|
2021
|
P/S
|
Promoting public awareness of cancer and barriers to treatment and challenges associated with sam... |
|
|
P/S
|
Pharmaceutical preparations for use in humans, namely, chemotherapeutics and biopharmaceuticals f... |
|
2020
|
P/S
|
Pharmaceutical preparations for use in humans, namely,
chemotherapeutics and biopharmaceuticals ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment and diagnosis of cancer and immunological diseases.... |
|
|
P/S
|
Pharmaceutical preparations for the treatment and diagnosis
of cancer and immunological diseases... |
|
|
P/S
|
Pharmaceutical preparations for the treatment and diagnosis of cancer and immunological diseases ... |
|
|
P/S
|
Pharmaceutical preparations for use in humans, namely,
chemotherapeutics and biopharmaceuticals;... |
|
|
P/S
|
Pharmaceutical preparations for use in humans, namely, chemotherapeutics and biopharmaceuticals; ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer. |
|
2019
|
P/S
|
Pharmaceutical preparations for the treatment of cancer |
|
|
P/S
|
Business administration of health reimbursement arrangements; providing business information rega... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparatio... |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment
of cancer; pharmaceutical preparati... |
